FDA approved Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation
Read more: FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors